Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

That's because CagriSema is made of one molecule of semaglutide, and one of a different molecule called cagrilintide. Both semaglutide and cagrilintide are significantly more complex to make than ...

Amycretin affects the same two targets as a Novo drug called cagrisema that recently missed expectations in a Phase 3 trial, ...

On Friday morning, Novo Nordisk unveiled the latest results from a clinical trial of CagriSema, an investigational drug ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Just over a month after its CagriSema readout disappointed analysts, Novo Nordisk released promising data for its obesity drug amycretin. The Danish pharmaceutical giant ended off the week on a high ...

The Street broadly expected the Redefine-1 trial of CagriSema to show ~25% weight ... selected ACCG-2671 as its lead oral small molecule amylin receptor agonist for obesity and related diseases.

On Friday morning, Novo Nordisk unveiled the latest results from a clinical trial of CagriSema, an investigational drug leveraging the foundational semaglutide molecule used in Wegovy ...